Moleculin Biotech Inc (MBRX) - Market Cap to Net Income Ratio

Moleculin Biotech Inc - graphic logo of issuer MBRX

Moleculin Biotech, Inc. (MBRX) is developing sustainable biochemistry to combat tumors by implementing waste-free synthesis and resource-efficient consumption. The price action, where the indicator stands at -0.30, coincides with strict FDA oversight and patent protection for Annamycin liposomal delivery. Growth prospects are driven by leukemia inhibitor trials (Phase 2), while R&D costs are already priced in on the US market.

MBRX moleculin.com: Price to Earnings Ratio in the range 07/04/2022 - 11/14/2026

Analytical breakdowns for Moleculin Biotech, Inc.

- market price and analyst price targets:
Market Price Moleculin|MBRX - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Moleculin Biotech, Inc.|MBRX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Net Asset Value per Share Moleculin Biotech|MBRX - Company Net Assets|Market Value to Book Value moleculin.com|MBRX - Aggregate Company Assets
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Moleculin Biotech, Inc.|MBRX - Long-Term Debt to Equity|Short-Term Debt to Equity Moleculin|MBRX - Company Aggregate Debts|Debts to Book Capitalization Moleculin Biotech, Inc.|MBRX - Company Long-Term Liabilities|Amount of Current Liabilities Moleculin Biotech|Critical Liquidity Ratio moleculin.com
- business earnings and investment ratios data:
MBRX - Company Net Income|Expected Net Profit Moleculin Biotech, Inc.|MBRX - Price to Earnings Ratio|Future Price to Earnings Multiple Moleculin|MBRX - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Moleculin Biotech, Inc.|MBRX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Moleculin Biotech|MBRX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months moleculin.com|MBRX - Earnings per share growth in current year|Expected net earnings per share growth next year Moleculin Biotech, Inc.
- issuer revenue and sales details:
MBRX - Company Revenue|Company Projected Revenue Moleculin|MBRX - P/S Multiple|Market Cap to Future Revenue Ratio Moleculin Biotech, Inc.
Summary company analysis:MBRX, moleculin.com
Manufactured products of Moleculin

Analyzing the business model of Moleculin Biotech, Inc. (MBRX) through the company's historical average P/E ratio allows for an assessment of the asset's market value relative to its net income. This ratio reflects the investment payback period, and for a pharmaceutical company utilizing outsourced development and distribution, this metric serves as an indicator of the efficiency of process delegation in the context of capitalizing on future therapeutic successes.

Competing companies

Market Cap to Earnings geron.com GERN|P/E Multiple NBTX|Bicycle Therapeutics PLC (BCYC) - Market Cap to Net Income Ratio|CytomX Therapeutics Inc - Price to Earnings Ratio|Perspective Tx (CATX) - Market Cap to Earnings|GNLX: Price to Earnings Ratio|Company Value to Net Income MOLN (molecularpartners.com)|oncolyticsbiotech.com (ONCY) - Price to Earnings Ratio|Market Cap to Net Income LSTA (Lisata Therapeutics, Inc.)|Price to Earnings Ratio Galera Therapeutics Inc.|Price to Earnings Ratio MTEM